BC Innovations | Aug 29, 2019
Distillery Techniques

STAT3-based gene signature to predict response to glioblastoma targeted therapy

TECHNIQUES CATEGORY: Biomarkers TECHNOLOGY: Gene profiling A STAT3-based gene expression signature could identify glioblastoma multiforme (GBM) patients that will respond to STAT3 inhibitors as monotherapies or in combination with IGF1R (insulin-like growth factor-1 receptor; CD221)...
BC Extra | Aug 7, 2019
Company News

Management tracks: Gilead's McHutchison joins Assembly as CEO; plus Lilly, Vor, HiberCell, insitro and more

Assembly Biosciences Inc. (NASDAQ:ASMB) gained $2.39 (20%) to $14.25 Wednesday after hiring John McHutchison as president and CEO, succeeding Derek Small. Gilead Sciences Inc. (NASDAQ:GILD) announced last month that McHutchison would step down as CSO...
BC Innovations | Apr 24, 2018
Distillery Therapeutics


INDICATION: Hepatic Cell culture and mouse studies suggest PDX could help treat hepatic steatosis. In a human hepatocyte-based assay of triglyceride accumulation induced by palmitic acid, PDX decreased triglyceride levels compared with vehicle. In a...
BC Week In Review | Feb 23, 2018
Clinical News

Roche reports Phase II data for bispecific DME candidate

Roche (SIX:ROG; OTCQX:RHHBY) reported data from the Phase II BOULEVARD trial to treat diabetic macular edema (DME) showing that once-monthly 6 mg intravitreal RG7716 for 20 weeks met the primary endpoint of improving mean best...
BC Innovations | Mar 16, 2017
Product R&D

Neo wave

The central thesis in the increasingly hot field of neoantigens is to pick mutations from patient tumors and turn them into personalized immunotherapies. While companies are staking out their space by defining how they will...
BC Innovations | Sep 15, 2016
Distillery Therapeutics

Therapeutics: Angiogenin ribonuclease RNase A family 5 (ANG)

Hematology INDICATION: Bone marrow transplant (BMT); poisoning Cell culture and mouse studies suggest ANG could help improve outcomes in BMT patients and treat radiation damage. In cultures of primary mouse hematopoietic stem cells (HSCs), recombinant...
BioCentury | May 23, 2016
Product Development

Provoking a response

Gritstone Oncology Inc. selected Immune Design Corp .'s ZVex technology to deliver personalized neoantigen therapies because targeting the antigens directly to dendritic cells with a viral vector could be the most immunogenic approach. Gritstone launched...
BC Extra | Nov 19, 2015
Company News

Genentech, Novartis to share ex-U.S. Fovista rights

The Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) exercised its option to share ex-U.S. rights to wet age-related macular degeneration (AMD) candidate Fovista pegpleranib with Novartis AG (NYSE:NVS; SIX:NOVN). The partners already market Lucentis ranibizumab...
BC Innovations | Apr 9, 2015
Translation in Brief

Super-additive silencing

Tekmira Pharmaceuticals Corp. has a dual-targeting RNAi that could treat hypertriglyceridemia more effectively than therapeutics that silence either target alone. The two-component product, TKM-HTG, contains RNAi components that separately target apolipoprotein C-III ( APOC3 ; APOCIII...
BioCentury | Mar 9, 2015

Persevering with ProstVac

After more than 20 years in clinical development, including over six years in the hands of Bavarian Nordic A/S , ProstVac rilimogene galvacirepvec found a potential commercial partner in Bristol-Myers Squibb Co. Whether BMS exercises its...
Items per page:
1 - 10 of 25